Schjesvold, F., Voorhees, P., Dimopoulos, M., Cohen, Y., Hungria, V., Sandhu, I., Lindsay, J., Baker, R., Suzuki, K., Kosugi, H., Levin, M.-D., Beksac, M., Stockerl-Goldstein, K., Magen, H., Oriol, A., Mikala, G., Garate, G., Theunissen, K., Spicka, I., Mylin, A., Hallam, S., Bringhen, S., Uttervall, K., Pula, B., Khan, A., Medvedova, E., Ye, J., Cowan, A., Moreau, P., Mateos, M.-V., Goldschmidt, H., Vieyra, D., Raval, A., Sha, L., Li, L., Rousseau, E., Dennis, R., Carson, R. and Rajkumar, S. (2026) “B09 | DARATUMUMAB MONOTHERAPY VS. ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: "AQUILA" OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION, IMWG 2020 PLUS CYTOGENETIC CRITERIA, AND AGE”, Haematologica. Pavia, Italy, 111(s2). doi: 10.3324/haematol.2026.s2.14042.